Home › Hemophilia › NCT07692217
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies (TG-INSIGHT With Joint POCUS)
Who can join
6 Months · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants with moderate or severe HA who are on prophylaxis with either weekly, biweekly, or every 4-weeks emicizumab or weekly efanesoctocog alfa for at least 2 months. * \>6 months of age Exclusion Criteria: * Participants with active FVIII inhibitor (\>0.5 BU/mL) * Presence of an additional bleeding disorder other than hemophilia A
About the study
This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.
What is being tested
- Half-life factor VIII based replacement therapy (drug)
- Non-FVIII based replacement therapy (drug)
Sponsor: University of Texas Southwestern Medical Center · Participants: 60 · Started: Jul 22, 2026
Contact the study team
- Jessica Garcia, MD · Phone: 214-456-7000
Official record on ClinicalTrials.gov — NCT07692217
Locations in the U.S.
| Texas | The University of Texas Southwestern Medical Center, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.